Business
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on
About this update from Koru Medical Systems, Inc.
[{"type":"text","content":" MAHWAH, N.J.--(BUSINESS WIRE)--\nKORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce data on the impact of the Freedom Infusion System on subcutaneous immunoglobulin (SCIg) therapy for primary immunodeficiency diseases (PIDD) to be presented at the National Home Infusion Association (NHIA) 2024 Conference. The conference will take place from March 23 to 27 in Austin, Texas.\n\n\nThe study, authored by KORU Medical, analyzed data from a large national specialty pharmacy, capturing drug receipts over 4.5 years for 3,787 US PIDD patients using KORU Medical FREEDOM60® and FreedomEdge® infusion systems for self-administered SCIg therapy. Ages ranged from 1 year to 98 years, with a mean of 50.1 years. Patient drug administration volumes ranged from 5mL to greater than 100mL with the majority of patients administering under 50mL. Adherence to SCIg therapy using the KORU Medical FREEDOM60® and FreedomEdge® infusion systems was calculated at 97%.\n\n\nThe abstract, titled \"Exploring the Impact of KORU Freedom Infusion Systems on Subcutaneous Immunoglobulin Therapy for Primary Immunodeficiency: Insights from a Large-Scale Database Analysis,” will be presented by Brent Rutland, Vice-President of Medical Affairs for KORU Medical. This study represents the largest cohort of PIDD patients in the literature. We believe it provides valuable insights into the effectiveness of KORU Medical’s Freedom Infusion System in promoting treatment compliance in large volume subcutaneous delivery.\n\n\n“These findings highlight the positive impact of KORU Medical’s Freedom Infusion System on subcutaneous immunoglobulin therapy for patients with primary immunodeficiency disease,\" said Brent Rutland, Vice President, Medical Affairs at KORU Medical. \"The high adherence rate underscores the effectiveness of KORU Medical’s pumps in promoting treatment compliance and improving patient outcomes. These results, with the KORU Freedom Infusion System, also demonstrate the company’s potential to support a broader range of developmental subcutaneous drug therapies.”\n\n\nAbout KORU Medical Systems\n\n\nKORU Medical develops, manufactures, and ...